ARS Pharmaceuticals Appoints Donn Casale as CEO, Replaces Richard Lowenthal
SPRY sits 18% above its 52-week low of $6.66.
Summary
ARS Pharmaceuticals announced a significant leadership change, appointing Donn Casale as its new CEO and replacing Richard Lowenthal, who was terminated without cause.
Key Events · Executive and Board Changes · SPRY
-
New CEO Appointed
Donn Casale, previously the company's President (appointed May 13, 2026), has been named Chief Executive Officer, effective immediately.
-
Former CEO Terminated
Richard Lowenthal was terminated from his position as CEO without cause, effective July 6, 2026.
-
Board Appointment
Mr. Casale was also concurrently appointed to the Board of Directors as a Class III director.
Analysis · SPRY · Life Sciences
The company has replaced its Chief Executive Officer, Richard Lowenthal, who was terminated without cause. Donn Casale, who was appointed President less than two months ago, has been rapidly promoted to CEO and also joins the Board. This significant leadership change follows a recent 23% stock plunge after the company's key product, Neffy, failed to secure new commercial agreements, suggesting the Board is taking decisive action in response to recent performance challenges.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRY was trading at $7.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $813.3M. The 52-week trading range was $6.66 to $18.63. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.